In February, the Wuhan Institute of Virology announced that it would patent the COVID-19 drug remdesivir, which was originally developed by the U.S. company Gilead Sciences as a treatment for Ebola. The institute had been studying the disease that was ravaging Wuhan province and they focused on two potential drugs that were “highly effective”: remdesivir and the anti-malarial chloroquine. In the announcement, they noted that they would not seek a patent on chloroquine.
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.